『MEDCast』のカバーアート

MEDCast

MEDCast

著者： MJH Life Sciences
無料で聴く

このコンテンツについて

 MEDCast is a healthcare program brought to you by http://HCPLive.com that features leading medical experts who discuss a range topic within a particular condition or medical disorder.© 博物学 生物科学 科学 自然・生態学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer

    Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
    2025/06/05
    Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic castration-resistant prostate cancer (nmCRPC) show darolutamide may offer superior tolerability with lower discontinuation rates and fewer drug interactions, while emphasizing the importance of critically evaluating real-world studies by examining methodology rather than just conclusions.
    続きを読む 一部表示
    32 分
  • Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME

    Real-World Treatment Strategies Using Next-Generation Therapies for Neovascular AMD and DME
    2025/05/28
    Ehsan Rahimy, MD; David G. Miller, MD, Michael Klufas, MD, discusses how real-world treatment strategies for neovascular AMD and DME with next-generation anti-VEGF therapies differ from clinical trials, including individualized loading dose approaches, extension interval considerations, and the challenges of balancing durability with appropriate monitoring.
    続きを読む 一部表示
    37 分
  • Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases

    Drying, Durability, and Disease Control: Evolving Metrics of Anti-VEGF Success in Retinal Diseases
    2025/05/28
    Ehsan Rahimy, MD; David G. Miller, MD, Esther Kim, MD, discusses how achieving retinal drying through anti-VEGF therapies remains a critical marker of treatment success in retinal diseases like AMD and DME, while highlighting the benefits of newer agents like aflibercept 8mg and faricimab for providing better durability and sustained disease control with reduced treatment burden.
    続きを読む 一部表示
    35 分

MEDCastに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。